Locations:
Search
By Mikkael Sekeres, MD, MS
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
“I don’t know if I’m looking forward to being 98.”
My 97-year-old patient revealed this to me during our first meeting in my clinic examination room.
“What do you mean?” I asked.
He rested both forearms on the high arms of his wheelchair, which caused his shoulders to hunch and gave the impression that he was about to spring into action. He spoke deliberately, choosing his words carefully. His eyes were rheumy but sharply focused, commanding my attention.
“I don’t want to end up… you know, blotto,” he said, quickly pantomiming a person slouched to one side of his chair, mouth open.
“Why do you think that might happen?” I asked.
“Because of my medical condition, or whatever you’re going to recommend I treat it with,” he answered, matter-of-factly…
Read the full New York Times column by Dr. Sekeres, Director of Cleveland Clinic Cancer Center’s Leukemia Program.
Advertisement
Advertisement
First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses
Global R&D efforts expanding first-line and relapse therapy options for patients
Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels
A case study on the value of access to novel therapies through clinical trials
Findings highlight an association between obesity and an increased incidence of moderate-severe disease
Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access 23456
Key learnings from DESTINY trials
Overall survival in patients treated since 2008 is nearly 20% higher than in earlier patients